Ceftiofur (Excenel, Naxcel)

Ceftiofur is a third-generation cephalosporin antibiotic developed specifically for veterinary use in food-producing animals. As a member of the beta-lactam antibiotic class, ceftiofur shares the fundamental mechanism of bacterial cell wall synthesis inhibition with penicillins while offering an extended spectrum of activity against both gram-positive and gram-negative pathogens. This broad-spectrum capability, combined with excellent tissue distribution and favorable pharmacokinetic properties, has established ceftiofur as a primary therapeutic option for treating serious bacterial infections in cattle and swine. The drug represents a significant advancement in veterinary antimicrobial therapy, providing potent activity against major respiratory and reproductive pathogens affecting livestock production.

The mechanism of action of ceftiofur involves high-affinity binding to penicillin-binding proteins (PBPs) in bacterial cell walls, disrupting peptidoglycan synthesis essential for cell wall integrity. Unlike earlier-generation cephalosporins and most penicillins, ceftiofur demonstrates remarkable stability against degradation by beta-lactamase enzymes produced by many resistant bacterial strains. This beta-lactamase stability significantly expands the effective spectrum to include organisms that would otherwise inactivate the antibiotic before therapeutic effects occur. The resulting bactericidal action rapidly eliminates susceptible pathogens when adequate drug concentrations reach the infection site.

Ceftiofur is available in several formulations tailored to specific therapeutic applications and production settings. Ceftiofur hydrochloride (Naxcel) is provided as a sterile powder requiring reconstitution before administration. Ceftiofur sodium offers similar characteristics with rapid systemic absorption. The ready-to-use sterile suspension formulation marketed as Excenel RTU provides convenience by eliminating reconstitution steps while maintaining therapeutic efficacy. Additionally, intramammary preparations including Spectramast LC for lactating cows and Spectramast DC for dry cow therapy address mastitis treatment and prevention needs in dairy operations. Each formulation has distinct indications, dosing protocols, and withdrawal requirements demanding careful attention.

Regulatory approval of ceftiofur covers multiple indications in cattle and swine, reflecting extensive safety and efficacy data supporting its use in these species. The drug requires a veterinary prescription and use within an established veterinarian-client-patient relationship. As a critically important antimicrobial according to World Health Organization classifications, ceftiofur use carries particular responsibility for antimicrobial stewardship to preserve its effectiveness for both veterinary and human medicine. Judicious use following labeled indications and dosing, combined with accurate record-keeping and withdrawal time compliance, supports responsible integration of this valuable therapeutic tool into livestock health programs.

Bovine respiratory disease (BRD) complex represents the primary indication for ceftiofur use in cattle, addressing one of the most economically significant health challenges in beef and dairy production. The drug demonstrates potent activity against the major bacterial pathogens associated with BRD, including Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. These organisms commonly cause severe pneumonia following viral respiratory infections or stress-induced immunosuppression in feedlot cattle, newly received calves, and dairy animals. Ceftiofur's excellent lung tissue penetration and sustained bactericidal activity make it particularly effective for treating established respiratory infections when administered according to labeled protocols.

Acute bovine metritis in dairy and beef cattle constitutes another approved therapeutic indication for ceftiofur. Postpartum uterine infections caused by Escherichia coli, Arcanobacterium pyogenes, and Fusobacterium necrophorum respond to ceftiofur treatment when initiated during the acute disease phase. The drug's systemic distribution provides effective concentrations in uterine tissues, addressing infections that could otherwise progress to septicemia or chronic reproductive problems. Treatment of metritis helps restore fertility and maintain production efficiency while reducing animal suffering from this common postpartum complication.

Interdigital necrobacillosis, commonly known as foot rot, is an approved indication reflecting ceftiofur's activity against the causative anaerobic pathogens. Fusobacterium necrophorum and Dichelobacter nodosus typically cause this painful condition that results in lameness and production losses in cattle. The extended spectrum of ceftiofur provides coverage for these organisms along with secondary bacterial invaders that may complicate foot infections. Single-dose or short-course treatment protocols offer practical advantages for managing foot rot in pasture or feedlot settings where repeated animal handling proves difficult.

In swine production, ceftiofur is approved for treating swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis, and Haemophilus parasuis. These pathogens cause severe pneumonia, pleuritis, and systemic infections responsible for significant mortality and production losses in pig herds. The drug's favorable pharmacokinetics in swine and activity against these major respiratory pathogens support its utility as a therapeutic option for acute bacterial pneumonia. Individual animal treatment remains the primary approach, though metaphylactic use in high-risk populations may be considered under veterinary guidance.

Mastitis treatment and prevention in dairy cattle represents an important intramammary application of ceftiofur. Spectramast LC is approved for treating clinical mastitis in lactating dairy cattle caused by coagulase-negative staphylococci and Streptococcus dysgalactiae. Spectramast DC provides dry cow therapy to eliminate existing intramammary infections and prevent new infections during the dry period. These targeted formulations deliver effective antibiotic concentrations directly to mammary tissue where infections develop, complementing systemic treatment approaches and supporting udder health management programs essential for dairy production quality.

Dosing protocols for ceftiofur vary by formulation, species, and specific indication being treated. For bovine respiratory disease using ceftiofur hydrochloride (Naxcel), the approved dose is 1.1 to 2.2 mg/kg body weight administered intramuscularly or subcutaneously once daily for 3 to 5 consecutive days. The higher end of the dose range is typically recommended for severe infections or when treating pathogens with elevated minimum inhibitory concentrations. Treatment should continue for at least 48 hours after clinical improvement is noted, with the full course completed even if animals appear recovered to prevent relapse and resistance development.

Excenel RTU (ceftiofur hydrochloride ready-to-use sterile suspension) provides a convenient formulation requiring no reconstitution. The approved cattle dosage for respiratory disease is 1.1 to 2.2 mg/kg intramuscularly in the posterior aspect of the ear or subcutaneously in the neck at 24-hour intervals for 3 to 5 days. Ear administration is preferred in beef cattle destined for slaughter as this injection site is removed during processing, eliminating concerns about injection site lesions in edible tissues. For acute metritis and foot rot, similar dosing protocols apply with treatment duration adjusted based on clinical response.

Swine dosing with ceftiofur follows weight-based calculations similar to cattle, with 3 to 5 mg/kg administered intramuscularly once daily for 3 consecutive days as the typical protocol for respiratory disease. Injection site selection in the neck region helps avoid carcass quality issues. Accurate weight estimation is particularly important in swine operations where animals are often treated in groups and individual weights may not be precisely known. Underdosing risks treatment failure and resistance selection, while overdosing increases adverse effect potential and drug costs.

Intramammary administration of ceftiofur for mastitis follows product-specific protocols. Spectramast LC is infused into affected quarters of lactating cows, with one syringe per infected quarter repeated at 24-hour intervals as directed. Proper technique includes complete milking of the quarter, teat end disinfection with alcohol, insertion of the cannula tip only partially into the teat canal, and gentle massage following infusion. Spectramast DC is administered to all four quarters at dry-off, providing extended antimicrobial protection throughout the dry period when new infection risk is elevated.

Proper injection technique protects both animal welfare and carcass quality. Subcutaneous administration in the neck using appropriate needle size (16-18 gauge, 1-1.5 inch length for adult cattle) deposits medication in tissues with minimal pain and tissue damage. When intramuscular injection is required, the neck muscles remain the preferred site over hindquarter muscles. Injection volumes should not exceed 15 mL per site in cattle, with sites rotated between treatments. Maintaining aseptic technique by using clean needles and wiping injection sites reduces infection risk at injection locations.

Withdrawal times for ceftiofur products demand careful attention to prevent violative residues. Excenel RTU and Naxcel in cattle require zero days slaughter withdrawal when used according to label directions and administered in the ear. However, subcutaneous neck or other administration sites require extended withdrawals of 2-4 days depending on the specific product. Spectramast LC carries a zero-day milk discard and 2-day slaughter withdrawal when used as directed. Spectramast DC requires a 16-day slaughter withdrawal. Swine slaughter withdrawal for injectable ceftiofur is typically 4 days. Extra-label use mandates extended withdrawal periods established by the prescribing veterinarian, and consultation with FARAD may be warranted for complex situations.

Ceftiofur demonstrates an excellent safety profile in food-producing animals when administered according to approved labeling, with adverse effects occurring infrequently in clinical use. The targeted mechanism of action affecting bacterial cell walls rather than mammalian cellular processes contributes to the wide therapeutic margin characteristic of beta-lactam antibiotics. Nevertheless, monitoring treated animals for unexpected reactions remains important, and recognition of potential adverse effects enables prompt intervention when problems do occur. Documentation of any adverse reactions supports both individual animal care and population-level safety surveillance.

Injection site reactions represent the most commonly observed adverse effect following parenteral ceftiofur administration. Local tissue inflammation typically manifests as transient swelling, firmness, or mild discomfort at injection sites. These reactions are generally self-limiting and resolve within days to weeks following treatment completion. The ready-to-use suspension formulation may cause somewhat more pronounced local reactions than reconstituted products due to formulation characteristics. Administration in the ear (when approved for the specific product) eliminates concerns about injection site lesions in marketed carcasses while still potentially causing temporary local effects.

Gastrointestinal disturbances are uncommon with ceftiofur but may occur, particularly at high doses or with prolonged treatment. Disruption of normal intestinal microflora can manifest as loose stools or decreased feed intake. In ruminants, the drug's primary elimination through metabolism rather than biliary excretion limits impact on rumen microorganisms compared to antibiotics that achieve high gut concentrations. Most gastrointestinal effects are mild and transient, resolving following treatment cessation without specific intervention. Severe or persistent diarrhea should prompt veterinary evaluation to assess for secondary complications.

Hypersensitivity reactions to ceftiofur can occur in animals with allergies to beta-lactam antibiotics, though such reactions are rare in food animal populations. Cross-reactivity between cephalosporins and penicillins exists but is less complete than cross-reactivity within the penicillin class itself. Clinical signs of allergic reactions may include urticaria, facial swelling, respiratory difficulty, and in severe cases, anaphylaxis with cardiovascular collapse. Animals with known previous reactions to penicillins or cephalosporins should not receive ceftiofur, and emergency treatment supplies including epinephrine should be available when treating animals with uncertain allergy history.

Species-specific adverse effects beyond injection site reactions are minimal with ceftiofur. Reproductive safety studies in cattle and swine have not demonstrated teratogenic effects at therapeutic doses, supporting use in pregnant animals when medically indicated. Milk from treated cows should be discarded during treatment and for the specified withdrawal period to prevent antibiotic residues in the food supply rather than due to any direct effect on milk quality. Young animals, including calves and piglets, generally tolerate ceftiofur well when dosed appropriately for body weight, though immature renal function may modestly extend drug elimination in neonates.

Ceftiofur is contraindicated in animals with known hypersensitivity to cephalosporin antibiotics or penicillins. While cross-reactivity between these beta-lactam classes is not absolute, sufficient immunological overlap exists that animals with documented penicillin allergies should be considered at elevated risk for cephalosporin reactions. Previous anaphylactic reactions to any beta-lactam antibiotic absolutely contraindicate ceftiofur use. A thorough treatment history should be obtained when available, and caution exercised when treating animals with uncertain exposure history to beta-lactam antibiotics. Having epinephrine available during initial treatment provides a safety measure for unexpected allergic reactions.

Specific production stage restrictions apply to ceftiofur use based on formulation characteristics and approved indications. The intramammary formulation Spectramast DC is approved only for dry cow therapy and must not be used in lactating cattle. Conversely, Spectramast LC is formulated for lactating cow mastitis treatment and is not intended for dry cow use. Using products outside their approved production stage indications constitutes extra-label use requiring veterinary prescription and potentially extended withdrawal times. Animals intended for slaughter must complete the full withdrawal period before marketing regardless of production stage.

Age and weight considerations influence ceftiofur suitability in certain populations. Very young calves and piglets with immature metabolic and excretory systems may handle drugs differently than mature animals, though ceftiofur is generally well-tolerated in young stock when appropriately dosed. Some product labels specify minimum age or weight requirements that should be followed. Severely debilitated or dehydrated animals may demonstrate altered drug distribution and elimination, potentially affecting both efficacy and safety. Veterinary assessment of overall patient status helps guide treatment decisions in compromised animals.

Concurrent disease states affecting renal function warrant consideration when prescribing ceftiofur, though the drug's primary metabolism to active metabolites reduces dependence on renal elimination compared to renally-excreted antibiotics. Animals with documented kidney disease represent a population requiring clinical judgment regarding dose adjustment or alternative antibiotic selection. Similarly, animals with severe hepatic compromise may metabolize ceftiofur differently than healthy animals. These situations are relatively uncommon in food animal practice but merit attention when they occur to optimize therapeutic outcomes while minimizing adverse effect risk.

Ceftiofur exhibits relatively few clinically significant drug interactions in food animal practice, though awareness of potential interactions supports optimal therapeutic outcomes. Bacteriostatic antibiotics including tetracyclines, macrolides, and phenicols theoretically may antagonize the bactericidal activity of ceftiofur by inhibiting the bacterial protein synthesis necessary for active cell division. Since beta-lactams exert maximal effect against dividing bacteria, concurrent bacteriostatic therapy could reduce ceftiofur efficacy. While this interaction's clinical significance varies by pathogen and infection type, simultaneous administration of bacteriostatic and bactericidal antibiotics is generally avoided unless specifically indicated by established treatment protocols.

Aminoglycoside antibiotics may be combined with ceftiofur for serious infections where synergistic bactericidal activity is desired. The combination provides enhanced killing of certain gram-negative pathogens and may be valuable in septicemic conditions or infections with organisms demonstrating intermediate susceptibility to either agent alone. However, physical mixing of these drugs in the same syringe should be avoided as chemical incompatibility may reduce activity of both agents. Separate injection sites and potentially staggered administration times optimize the synergistic benefit while maintaining individual drug stability and activity.

Loop diuretics such as furosemide may increase nephrotoxicity risk when administered with cephalosporins, though this interaction has greater relevance in companion animal and human medicine than typical food animal scenarios. Animals receiving diuretic therapy for conditions like pulmonary edema should be monitored for renal function changes if concurrent ceftiofur treatment is necessary. The relatively short treatment courses typical of food animal ceftiofur use limit cumulative interaction risk compared to prolonged antibiotic therapy.

Probenecid inhibits renal tubular secretion and can prolong cephalosporin half-life by reducing drug elimination. While this interaction is sometimes therapeutically exploited in human medicine to extend antibiotic blood levels, probenecid use in food animals is uncommon, making this interaction primarily of academic interest in veterinary practice. Documentation of all concurrent medications in treatment records supports comprehensive patient management and helps identify any unexpected interactions affecting treatment response or withdrawal calculations.

Human safety during ceftiofur handling requires attention to prevent occupational health risks. Individuals with known beta-lactam antibiotic allergies should avoid direct contact with ceftiofur products and have others perform medication handling duties. Skin contact with the drug may cause sensitization, and subsequent exposures could trigger allergic reactions. Personal protective equipment including gloves should be worn during preparation and administration. Accidental self-injection constitutes a medical emergency requiring immediate medical evaluation, with information about the specific drug provided to healthcare personnel. Washing hands after handling and avoiding contact with eyes or mucous membranes represents standard precautions.

Food safety responsibilities extend to all aspects of ceftiofur use in production animals. Strict adherence to withdrawal times ensures meat and milk from treated animals do not contain violative antibiotic residues when entering the human food supply. Treatment records must include animal identification, drug name and concentration, dose administered, route, date(s) of treatment, and calculated withdrawal date for each treated animal. Milk from treated dairy cows must be diverted from the bulk tank during treatment and the withdrawal period. Treated animals requiring slaughter before withdrawal completion must not enter the food chain through normal marketing channels.

Antimicrobial stewardship principles apply particularly strongly to ceftiofur as a critically important antibiotic class. Third-generation cephalosporins are considered among the highest priority antimicrobials for human medicine, making their veterinary use subject to heightened responsibility. Use should be limited to situations where susceptible pathogens are confirmed or strongly suspected based on clinical presentation and farm history. When culture and sensitivity testing is practical, it should guide therapy selection. Completing full treatment courses at appropriate doses prevents relapse and limits resistance selection pressure compared to underdosing or abbreviated treatment.

Environmental considerations include proper disposal of unused medication, empty containers, and injection supplies. Cephalosporins in the environment contribute to resistance selection pressure in environmental bacterial populations. Following label directions for container disposal and using appropriate pharmaceutical waste channels when available supports environmental protection. In production settings, treatment areas should be cleaned to prevent inadvertent medication exposure to non-target animals.

Resistance monitoring at both herd and industry levels helps track the continued effectiveness of ceftiofur against target pathogens. Reporting treatment failures to veterinarians allows investigation of potential resistance development. Bacterial culture and sensitivity testing from non-responsive cases provides data on emerging resistance patterns. Participation in national surveillance programs contributes to understanding resistance trends that inform treatment guidelines. Responsible ceftiofur use by individual producers collectively maintains this valuable therapeutic option for the entire livestock industry.

Storage requirements for ceftiofur products vary by formulation, with proper handling essential for maintaining drug potency and efficacy. Ceftiofur hydrochloride powder (Naxcel) should be stored at controlled room temperature prior to reconstitution, protected from light and excessive heat or cold. The ready-to-use suspension (Excenel RTU) requires storage at 2-25°C (36-77°F), with protection from freezing as freezing may damage the suspension characteristics. Intramammary preparations should be stored according to individual product labels, typically at room temperature away from direct sunlight. All products should be kept in original packaging until use.

Reconstituted ceftiofur solutions have limited stability requiring careful attention to beyond-use dating. Naxcel reconstituted with sterile water maintains potency for 12 hours at room temperature or 7 days under refrigeration. The reconstitution date and time should be recorded directly on the vial along with the calculated expiration date and time. Ready-to-use products maintain stability through the labeled expiration date when stored properly, but should be discarded if visible changes in color, consistency, or clarity develop. Intramammary syringes should be inspected for damaged packaging before use.

Multi-dose vial handling requires aseptic technique to prevent contamination. Wiping the rubber stopper with alcohol before each withdrawal limits introduction of environmental bacteria. Using a clean needle for each withdrawal prevents cross-contamination between the vial and previously treated animals. Partially used vials should be labeled with the date first opened and discarded according to product-specific instructions or within 28 days, whichever comes first. Visual inspection before each use ensures no particulate matter or discoloration has developed indicating degradation.

Disposal of ceftiofur products and associated materials requires compliance with applicable regulations. Unused or expired medication should not be disposed of in regular trash or poured down drains. Many jurisdictions have pharmaceutical take-back programs or specific guidance for agricultural medication disposal. Empty containers should be triple-rinsed and disposed of according to label directions. Used needles and syringes require disposal in approved sharps containers. Proper disposal protects environmental quality and prevents antimicrobial contamination of water sources or soil.

Species-specific dosing considerations for ceftiofur reflect pharmacokinetic differences between cattle and swine, the two primary approved target species. Cattle generally receive the labeled dose range of 1.1-2.2 mg/kg for systemic infections, with dose selection based on infection severity, likely pathogen susceptibility, and individual patient factors. Swine dosing in the 3-5 mg/kg range reflects species differences in drug distribution and elimination. These labeled doses result from extensive pharmacokinetic and clinical studies establishing effective therapeutic regimens for each species.

Breed-specific sensitivities to ceftiofur are not well-documented in cattle or swine, with the drug generally well-tolerated across diverse breeds within each species. However, individual animals may show variable responses regardless of breed. Draft breeds with greater body mass may require larger absolute doses, while miniature or undersized animals need careful weight-based dosing to avoid overdosing. Exotic or minor breeds used in specialty production may have less documented pharmacokinetic data, though using labeled doses as a starting point with veterinary oversight remains appropriate.

Production type influences ceftiofur use considerations beyond species and breed. Dairy cattle operations must carefully manage milk withdrawal and bulk tank contamination risks, with robust protocols for identifying and segregating treated cows. Beef cattle in feedlot versus pasture settings face different disease pressures and handling constraints affecting treatment logistics. Swine production systems ranging from farrow-to-finish to specialized growing operations have distinct disease challenges and treatment opportunities. Understanding the production context helps optimize ceftiofur application for specific operations.

Age-related considerations affect ceftiofur pharmacokinetics and dosing decisions. Neonatal calves and piglets may demonstrate prolonged drug half-life due to immature hepatic metabolism and renal function, though standard labeled doses are generally appropriate with monitoring for adverse effects. Geriatric animals with declining organ function similarly may handle drugs differently than younger adults. The extended activity of ceftiofur's active metabolites provides sustained antibacterial effect that accommodates some variability in drug processing between individuals and age groups while maintaining therapeutic efficacy against susceptible pathogens.

Other third-generation cephalosporins provide alternatives to ceftiofur with similar broad-spectrum activity, though ceftiofur remains unique as the only member of this class approved for food animal use in many countries. Ceftiofur crystalline free acid (Excede) represents a modified ceftiofur formulation providing extended-release characteristics discussed separately. In regions where additional cephalosporins are approved, veterinarians may select among options based on specific pathogen susceptibility, pharmacokinetic properties, and practical considerations for particular clinical situations.

First and second-generation cephalosporins offer alternatives with differing spectra of activity. Cephapirin is approved for intramammary use in dairy cattle, providing coverage against gram-positive mastitis pathogens with distinct withdrawal characteristics. These earlier-generation agents generally demonstrate narrower gram-negative coverage than ceftiofur but may suffice for infections where gram-positive organisms predominate. Selecting narrower-spectrum agents when appropriate aligns with antimicrobial stewardship principles by preserving broader-spectrum options for situations requiring them.

Penicillin-class antibiotics represent beta-lactam alternatives to cephalosporins for susceptible infections. Ampicillin and amoxicillin provide aminopenicillin options with activity against some gram-negative organisms, though beta-lactamase-producing strains often show resistance that would not affect ceftiofur. Natural penicillins including procaine penicillin G target primarily gram-positive organisms and may suffice for infections known or suspected to involve only susceptible gram-positive pathogens. Consideration of likely pathogens, susceptibility patterns, and stewardship principles guides selection among available beta-lactam options for specific clinical scenarios.